Ver­ri­ca hits an­oth­er bump in the road with CMO re­lat­ed let­ter from FDA

The FDA has re­ject­ed Ver­ri­ca’s new drug ap­pli­ca­tion for VP-102 again, with the com­pa­ny pin­ning the CRL on prob­lems at a CMO that it was part­nered with, the com­pa­ny an­nounced Mon­day.

The FDA didn’t raise is­sues that di­rect­ly re­late to the man­u­fac­tur­ing of VP-102, the com­pa­ny said, but raised “gen­er­al qual­i­ty is­sues” at the CMO’s fa­cil­i­ty. There were al­so no clin­i­cal con­cerns, it said, or need to col­lect more da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER